- Congresses
- IMCAS Asia - June 2025
- IMCAS China - July 2025
- IMCAS World Congress - January 2026
- IMCAS Americas - March 2026
- Masterclasses
- IMCAS India - November 2025
- Congresses
- IMCAS Asia - June 2025
- IMCAS China - July 2025
- IMCAS World Congress - January 2026
- IMCAS Americas - March 2026
- Masterclasses
- IMCAS India - November 2025

IMCAS Academy

Introduction
Evaluation
Register
Program
Speakers
Gala
Plan your trip
Sponsor list
Accreditation

GO BACK

IMCAS Asia 2025
Program

Adapt the schedule of the livestreamed class/congress to your time zone

Time zone reference: (UTC+07:00) Asia, Bangkok

Time zone

Time zone:Change time zone

If you are logged in, change your default time zone in your account

GLP-1 and weight loss

Room: Room 4 - Level 2
Date: Sunday 8 June 2025 at 15:00 to 16:00
Format: FOCUS SESSION > lectures covering a major topic of the congress

Chairs

Dr Roger CHEN

Endocrinologist

Australia

Dr Simone MAY

Austria

Lectures of the session

Hours	Speakers	Lecture title	Abstract	Number
15:00	Dr Roger CHEN	Meet the expert: From GLP-1 to GIP/GLP-1 - Unveiling GIP's emerging role in obesity and beyond	View	148813
15:15	Dr Hugues CARTIER	GLP-1: Yes or no to injectables for facial hollowing?		148812
15:30	Dr Chiranjiv CHHABRA	Integrating GLP-1 receptor agonists with noninvasive body countoring modalities for a holistic, more effective, and faster outcome	View	148815
15:45		Discussion and Q&A		147036

Go to previous session

Go to next session

Recommended sessions

Anatomy for injections

Beauty norms

Combined treatments

Energy-based devices (EBD)

Microbiome

Dr Roger CHEN

Endocrinologist

Australia

Other author(s) :

Meet the expert: From GLP-1 to GIP/GLP-1 - Unveiling GIP's emerging role in obesity and beyond

Objectives: This session will review the evolving scientific understanding of incretin-based therapies, with a focus on GIP (Glucose-dependent Insulinotropic Polypeptide).

Emerging clinical data on the role of GIP in advancing the treatment landscape of obesity and other weight-related co-morbidities will be reviewed.

Introduction: Advances in incretin-based therapies have led to the development of dual Glucose-dependent Insulinotropic Polypeptide (GIP)/Glucagon-like peptide-1 (GLP-1) receptor agonists, representing a new frontier in obesity management. While GLP-1 receptor agonists have shown clinical success, the addition of GIP to a GLP-1 receptor agonistsmay offer synergistic benefits through distinct and complementary mechanisms that may enhance treatment outcomes.

Materials / method: The emerging role of GIP in obesity and obesity-related comorbidities will be reviewed.

Results: GIP acts on multiple tissues, notably adipose tissue where it contributes directly to improved lipid buffering capacity and body composition. In the central nervous system, GIP may synergistically reduce food intake while attenuating GLP-1-induced nausea, potentially improving overall tolerability. Therapies which target dual incretin receptors appear to potentially overcome efficacy limitations which may be seen with selective with GLP-1 monotherapy.

Conclusion: Efficacy data using Glucose-dependent Insulinotropic Polypeptide (GIP)/Glucagon-like peptide-1 (GLP-1) receptor agonists have led to a resurgence of research on the fascinating and emerging role of GIP in obesity

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No
Please specify entities (individual, company, society): As

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work is presented thanks to the support of: I am a speaker for or on advisory boards for Abbott, Astra Zeneca, Bayer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Sanofi, Zuellig Pharma

Dr Hugues CARTIER

Dermatologist

France

Other author(s) :

GLP-1: Yes or no to injectables for facial hollowing?

Dr Chiranjiv CHHABRA

Dermatologist

India

Other author(s) :

Integrating GLP-1 receptor agonists with noninvasive body countoring modalities for a holistic, more effective, and faster outcome

Objectives: GLP 1 receptor agonists are as a boon for individuals suffering from obesity or overweight .A large section of people with obesitty ,who want fat loss through non invasive body countouring modalities yaketaking very long to reacht their target weight and shape because of difficulty in persisting with changed diet plans . The GLP 1 drugs reduce appetite , food cravings and result in upto 25 % weight loss.Rapid loss results in skin laxity and muscle loss . Thus adding technologies for skin tightening , muscle stregthening and localized fat loss are beneficial in achieving a holistic outcome

Introduction: Glucagon-like peptide-1 (GLP-1) receptor agonists have revolutionized the treatment of obesity by promoting significant weight loss.Results of Non invasive fat loss modalities like Cryolipolysis,Green light laser,RF or Cavitation can be improved by adding these medications.Also rapid weight reduction induced by these medications often leads to aesthetic challenges like volume loss, skin laxity, and body contour irregularities. These consequences of GLP-1-induced weight loss can be minimised by modalities for tightening and muscle toning modalities like MNRF,RF and HIFEM.

Materials / method: As a scientific fat loss clinic we are integrating GLP-1 Rec agonist with other modalities.Identify patients with BMI above 29 .Their Hb1AC can be in range or raised. Few investigations are done and they are suggested a comprehensive plan with GLP -1&GIP rec Agonist along with the required modality.Their doses is monitored by a team of physicians and endocrinologist.During the treatment we identify key aesthetic concerns associated with GLP-1-induced weight loss and and depending on that add modalities like dermal fillers, biostimulatory agents and energy-based devices.

Results: A combination of GLP-1 Rec agonist along with other modalities delivers faster and more gratifying results instead of any standalone treatment.

Conclusion: As GLP-1 agonists become a key in treating obesity, their aesthetic implications have initiated a proactive response from aestheticians. To address facial volume loss, skin laxity, and body contour challenges we need combination of injectable treatments, energy-based devices, and, in some cases, surgical interventions. Future research should focus on understanding the molecular mechanisms of skin and fat changes and developing protocols &guidelines for treating this unique patient population

Disclosures

Did you receive any funding to support your research for this TOPIC?
No

Were you provided with any honoraria, payment or other compensation for your work on this study?
No

Do you have any financial relationship with any entity which may closely compete with the medications, materials or instruments covered by your study?
No

Do you own or have you applied for any patents in conjunction with the instruments, medications or materials discussed in your study?
No

This work was not supported by any direct or non direct funding. It is under the author's own responsability

Discussion and Q&A

CONGRESS

N O W

IN BANGKOK

You have a question?

Quickly find your answer in our FAQ

Congresses

IMCAS Asia
IMCAS China
IMCAS World Congress
IMCAS Americas

About

Company
Privacy Policy
Legal information

Academy

Home
Courses
Webinars
Explore
Blog

Grant

Educational grant

Get in touch

Username/Email

Password

Keep me logged in

Forgot password ? Do not have an account yet? Sign up now

Keep me logged in

academy.Do_not_have_an_account_yet Sign up now

IMCAS Asia 2025 Program

GLP-1 and weight loss

Chairs

Lectures of the session

Recommended sessions

IMCAS Asia 2025
Program